Christophe dombu
Stock Analyst at Kepler Capital
(0.15)
# 4,594
Out of 4,698 analysts
185
Total ratings
41.2%
Success rate
-10.6%
Average return
Main Sectors:
Stocks Rated by Christophe dombu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNN Smith & Nephew | Downgraded: Hold | n/a | $28.69 | - | 1 | Jun 4, 2026 | |
| LON: 0QBO Coloplast A/S | Initiated Coverage: Buy | kr 482.00 | kr 473.28 | +1.84% | 1 | May 20, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €810.00 | €907.60 | -10.75% | 33 | May 7, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | €23.50 | €25.00 | -6.00% | 19 | May 7, 2026 | |
| LON: SN Smith & Nephew plc | Maintained: Buy | 1,462p | 1,055p | +38.64% | 5 | May 6, 2026 | |
| EPA: VIRP Virbac SA | Maintained: Buy | €415.00 | €321.00 | +29.28% | 6 | Apr 17, 2026 | |
| SWX: KURN Kuros Biosciences AG | Maintained: Buy | CHF 38.00 | CHF 18.11 | +109.83% | 9 | Apr 14, 2026 | |
| SWX: BSLN Basilea Pharmaceutica AG | Maintained: Buy | CHF 69.00 → CHF 70.00 | CHF 65.80 | +6.38% | 27 | Apr 13, 2026 | |
| LON: 0HNZ Fagron NV | Maintained: Buy | €27.50 | €22.00 | +25.00% | 2 | Apr 9, 2026 | |
| EPA: MAAT MaaT Pharma SA | Maintained: Buy | €17.00 | €3.05 | +458.29% | 26 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €14.30 | €4.43 | +222.80% | 25 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.76 | +591.25% | 26 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €0.10 → €0.01 | €0.69 | n/a | 5 | Feb 7, 2025 |
Smith & Nephew
Jun 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $28.69
Upside: -
Coloplast A/S
May 20, 2026
Initiated Coverage: Buy
Price Target: kr 482.00
Current: kr 473.28
Upside: +1.84%
argenx SE
May 7, 2026
Maintained: Buy
Price Target: €810.00
Current: €907.60
Upside: -10.75%
Lakefront Biotherapeutics NV
May 7, 2026
Maintained: Sell
Price Target: €23.50
Current: €25.00
Upside: -6.00%
Smith & Nephew plc
May 6, 2026
Maintained: Buy
Price Target: 1,462p
Current: 1,055p
Upside: +38.64%
Virbac SA
Apr 17, 2026
Maintained: Buy
Price Target: €415.00
Current: €321.00
Upside: +29.28%
Kuros Biosciences AG
Apr 14, 2026
Maintained: Buy
Price Target: CHF 38.00
Current: CHF 18.11
Upside: +109.83%
Basilea Pharmaceutica AG
Apr 13, 2026
Maintained: Buy
Price Target: CHF 69.00 → CHF 70.00
Current: CHF 65.80
Upside: +6.38%
Fagron NV
Apr 9, 2026
Maintained: Buy
Price Target: €27.50
Current: €22.00
Upside: +25.00%
MaaT Pharma SA
Mar 31, 2026
Maintained: Buy
Price Target: €17.00
Current: €3.05
Upside: +458.29%
Mar 26, 2026
Maintained: Buy
Price Target: €14.30
Current: €4.43
Upside: +222.80%
Mar 20, 2026
Maintained: Buy
Price Target: $12
Current: $1.76
Upside: +591.25%
Feb 7, 2025
Downgraded: Sell
Price Target: €0.10 → €0.01
Current: €0.69
Upside: n/a